- Selumetinib Cleared for Adults With Neurofibromatosis Type 1 Medscape
- FDA Approves Selumetinib for Adults With Neurofibromatosis Type 1 The American Journal of Managed Care® (AJMC®)
- AstraZeneca says Koselugo (Selumetinib) approved in the US MarketScreener
- Key facts: AstraZeneca’s Koselugo gains FDA approval; stock rises 1.4% TradingView
- AstraZeneca receives US FDA approval for Koselugo in adults with NF1 Investing.com